Compare Stocks

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
ANVS Annovis Bio	$9.96 +1.1%	$10.36	$5.42 ▼ $22.49	$109.66M	1.59	263,081 shs	71,240 shs
ASPCF Acerus Pharmaceuticals	$0.22	$0.22	$0.22 ▼ $8.16	$1.70M	0.69	1,500 shs	N/A
DFFN Diffusion Pharmaceuticals		$4.64	$2.76 ▼ $7.40	$8.98M	1.78	10,937 shs	351,000 shs
NOVN Novan	$0.00	$0.00	$0.08 ▼ $3.33	$22K	-0.06	602,421 shs	N/A

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-88.34%
ANVS Annovis Bio	+8.93%	-19.02%	+9.78%	-15.48%	-33.24%
ASPCF Acerus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
DFFN Diffusion Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-37.59%
NOVN Novan	0.00%	0.00%	0.00%	+166.67%	-99.94%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	1.6455 of 5 stars	3.4	1.0	0.0	0.0	3.1	1.7	0.6
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NOVN Novan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
ANVS Annovis Bio	2.75	Moderate Buy	$27.75	178.61% Upside
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A
NOVN Novan	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest NOVN, ANVS, DFFN, ADMP, and ASPCF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/2/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
3/21/2024	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
2/28/2024	ANVS Annovis Bio	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$9.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
ANVS Annovis Bio	N/A	N/A	N/A	N/A	($0.73) per share	N/A
ASPCF Acerus Pharmaceuticals	$2.12M	0.80	N/A	N/A	($3.38) per share	-0.07
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	$6.97 per share	N/A
NOVN Novan	$24.71M	0.00	N/A	N/A	$0.19 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
ANVS Annovis Bio	-$56.20M	-$6.22	N/A	N/A	N/A	N/A	-446.06%	-257.97%	5/9/2024 (Estimated)
ASPCF Acerus Pharmaceuticals	-$33.82M	-$3.57	N/A	∞	N/A	-924.33%	N/A	-74.62%	N/A
DFFN Diffusion Pharmaceuticals	-$15.59M	N/A	0.00	N/A	N/A	N/A	-69.96%	-62.98%	N/A
NOVN Novan	-$31.31M	-$1.32	N/A	N/A	N/A	-128.61%	-700.28%	-39.58%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
ASPCF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DFFN Diffusion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NOVN Novan	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
ANVS Annovis Bio	N/A	2.39	2.39
ASPCF Acerus Pharmaceuticals	N/A	0.67	0.34
DFFN Diffusion Pharmaceuticals	N/A	10.71	10.71
NOVN Novan	N/A	0.74	0.72

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
ANVS Annovis Bio	15.83%
ASPCF Acerus Pharmaceuticals	N/A
DFFN Diffusion Pharmaceuticals	9.95%
NOVN Novan	14.51%

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
ANVS Annovis Bio	38.30%
ASPCF Acerus Pharmaceuticals	N/A
DFFN Diffusion Pharmaceuticals	1.80%
NOVN Novan	1.30%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
ANVS Annovis Bio	5	11.01 million	6.79 million	Optionable
ASPCF Acerus Pharmaceuticals	14	7.71 million	N/A	Not Optionable
DFFN Diffusion Pharmaceuticals	13	2.04 million	2.00 million	Not Optionable
NOVN Novan	90	28.02 million	27.65 million	Not Optionable

NOVN, ANVS, DFFN, ADMP, and ASPCF Headlines

Source	Headline
	StockNews.com Begins Coverage on Novan (NASDAQ:NOVN) americanbankingnews.com - April 15 at 2:14 AM
	Novartis AG wsj.com - February 27 at 7:11 PM
	Novartis AG Registered Shares morningstar.com - February 16 at 10:42 PM
	Novartis AG Registered Shares NOVN morningstar.com - October 31 at 10:41 PM
	Novan: Regulation Fd Disclosure, Financial Statements And Exhibits cbonds.com - October 25 at 2:54 PM
	Novan reaches deals to sell assets in bankruptcy case bizjournals.com - September 8 at 1:15 PM
	Firm Retention Summary: Novan msn.com - August 8 at 7:07 AM
	Novan (NOVN) Price Target Increased by 43.52% to 15.81 msn.com - August 3 at 11:15 AM
	Novan files patent for a composition and method of treating skin pharmaceutical-technology.com - August 1 at 6:46 AM
	Insider Sale Alert: Novan Inc. [NOVN] – Is it Time to sell? knoxdaily.com - July 25 at 9:51 PM
	NOVN short interest surges, indicating growing pessimism among investors knoxdaily.com - July 21 at 12:48 PM
	NOVN stock rated an Overweight by Cantor Fitzgerald knoxdaily.com - July 18 at 9:22 AM
	Novan Shares Hit 52-Week Low After Bankruptcy Declaration marketwatch.com - July 17 at 2:13 PM
	Durham biotech Novan to sell assets, files for bankruptcy wraltechwire.com - July 17 at 9:12 AM
	Potential Price Increase for Novan Inc. (NOVN) After Recent Insider Activity knoxdaily.com - July 11 at 8:16 PM
	Novan Inc. [NOVN] Investment Guide: What You Need to Know knoxdaily.com - July 3 at 8:38 PM
	CIMB appoints Novan Amirudin as CIMB Investment Bank CEO malaymail.com - June 16 at 6:17 PM
	CIMB appoints Novan Amirudin as CEO of CIMB Investment Bank thestar.com.my - June 16 at 6:17 PM
	Novan Amirudin new CIMB Investment Bank CEO freemalaysiatoday.com - June 16 at 6:17 PM
	Durham pharma Novan slashes 50% of workforce, mulls sale of assets wraltechwire.com - June 1 at 12:34 PM
	Novan cuts 50% of its workforce to extend runway bizjournals.com - June 1 at 12:34 PM
	Novan drops 13%, will reduce workforce by 50% msn.com - June 1 at 12:34 PM
	Novan To "Sharpen" Focus, Resources On Berdazimer Gel markets.businessinsider.com - May 31 at 9:34 PM
	Novan Focuses Strategic Direction and Announces Restructuring finance.yahoo.com - May 31 at 4:33 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Annovis Bio

NYSE:ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Acerus Pharmaceuticals

OTCMKTS:ASPCF

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Diffusion Pharmaceuticals

NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Novan

NASDAQ:NOVN

Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial